MX2020011308A - Composiciones solidas que comprenden un agonista de peptido-1 similar al glucagon humano (glp-1) y una sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico. - Google Patents
Composiciones solidas que comprenden un agonista de peptido-1 similar al glucagon humano (glp-1) y una sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico.Info
- Publication number
- MX2020011308A MX2020011308A MX2020011308A MX2020011308A MX2020011308A MX 2020011308 A MX2020011308 A MX 2020011308A MX 2020011308 A MX2020011308 A MX 2020011308A MX 2020011308 A MX2020011308 A MX 2020011308A MX 2020011308 A MX2020011308 A MX 2020011308A
- Authority
- MX
- Mexico
- Prior art keywords
- hydroxybenzoyl
- glp
- agonist
- amino
- salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Abstract
La invención se refiere a composiciones farmacéuticas que comprenden un agonista de GLP-1 y una sal del ácido N-(8-(2-hidroxibenzoil)amino)caprílico. La invención se refiere además a procesos para la preparación de las composiciones, y a su uso en medicina.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18171046 | 2018-05-07 | ||
PCT/EP2019/061502 WO2019215063A1 (en) | 2018-05-07 | 2019-05-06 | Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020011308A true MX2020011308A (es) | 2020-11-18 |
Family
ID=62134107
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020011308A MX2020011308A (es) | 2018-05-07 | 2019-05-06 | Composiciones solidas que comprenden un agonista de peptido-1 similar al glucagon humano (glp-1) y una sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico. |
Country Status (19)
Country | Link |
---|---|
US (2) | US11622996B2 (es) |
EP (1) | EP3790575A1 (es) |
JP (2) | JP7164628B2 (es) |
KR (1) | KR20210008353A (es) |
CN (1) | CN112153979A (es) |
AR (1) | AR115283A1 (es) |
AU (1) | AU2019264783A1 (es) |
BR (1) | BR112020021717A2 (es) |
CA (1) | CA3097944A1 (es) |
CL (1) | CL2020002797A1 (es) |
CO (1) | CO2020014570A2 (es) |
IL (1) | IL277857A (es) |
MA (1) | MA52556A (es) |
MX (1) | MX2020011308A (es) |
PE (1) | PE20211794A1 (es) |
PH (1) | PH12020551691A1 (es) |
SG (1) | SG11202009978WA (es) |
TW (1) | TWI829687B (es) |
WO (1) | WO2019215063A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110642935A (zh) * | 2019-09-25 | 2020-01-03 | 成都奥达生物科技有限公司 | 一种替瑞帕肽类似物 |
US20230165939A1 (en) | 2020-04-29 | 2023-06-01 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist and histidine |
TW202227474A (zh) | 2020-12-18 | 2022-07-16 | 丹麥商諾佛 儂迪克股份有限公司 | Glp-1及澱粉素受體之共促效劑 |
CN113171446B (zh) * | 2021-05-06 | 2022-03-29 | 合肥天汇孵化科技有限公司 | 利拉鲁肽组合物及其用途 |
EP4360645A1 (en) * | 2021-06-25 | 2024-05-01 | Gan & Lee Pharmaceuticals Co., Ltd. | Pharmaceutical composition containing glp-1 compound |
WO2023065231A1 (en) * | 2021-10-21 | 2023-04-27 | Guangzhou Dazhou Biomedicine Ltd. | Oral delivery of therapeutic agents |
WO2023217744A1 (en) | 2022-05-10 | 2023-11-16 | Novo Nordisk A/S | Prodrugs of glp-1 polypeptide and uses thereof |
WO2024008904A2 (en) * | 2022-07-08 | 2024-01-11 | Novo Nordisk A/S | Highly potent isvd compounds capable of substituting for fviii(a) |
Family Cites Families (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0506792B1 (en) | 1989-12-21 | 1995-05-17 | Novo Nordisk A/S | Insulin preparations containing nicotinic acid or nicotinamide |
DK39892D0 (da) | 1992-03-25 | 1992-03-25 | Bernard Thorens | Peptid |
US6284727B1 (en) | 1993-04-07 | 2001-09-04 | Scios, Inc. | Prolonged delivery of peptides |
WO1996020005A1 (en) * | 1994-12-23 | 1996-07-04 | Novo Nordisk A/S | Protracted glp-1 compositions |
US5869602A (en) | 1995-03-17 | 1999-02-09 | Novo Nordisk A/S | Peptide derivatives |
US5650386A (en) | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
DE19530865A1 (de) | 1995-08-22 | 1997-02-27 | Michael Dr Med Nauck | Wirkstoff sowie Mittel zur parenteralen Ernährung |
UA72181C2 (uk) | 1996-08-30 | 2005-02-15 | Ново Нордіск А/С | Похідна глюкагоноподібного пептиду-1 (варіанти), фармацевтична композиція та спосіб одержання лікувального засобу (варіанти), спосіб лікування діабету (варіанти) і ожиріння |
WO1999043708A1 (en) | 1998-02-27 | 1999-09-02 | Novo Nordisk A/S | Glp-1 derivatives of glp-1 and exendin with protracted profile of action |
ATE466027T1 (de) | 1998-02-27 | 2010-05-15 | Novo Nordisk As | Abkömmlinge von glp-1 analogen |
EP1062240B1 (en) | 1998-02-27 | 2010-04-28 | Novo Nordisk A/S | N-terminally modified glp-1 derivatives |
DE69916811T2 (de) | 1998-02-27 | 2005-04-14 | Novo Nordisk A/S | Glp-1 derivate mit einem helix-gehalt über 25 %, die partiell strukturierte mizellenartige aggregate bilden |
BR9913857A (pt) * | 1998-09-17 | 2001-06-12 | Lilly Co Eli | Formulações de proteìna |
ATE309197T1 (de) | 1999-02-05 | 2005-11-15 | Emisphere Tech Inc | Verfahren zur herstellung alkylierter salicylamide |
WO2000062759A1 (en) | 1999-04-16 | 2000-10-26 | Novo Nordisk A/S | Dry, mouldable drug formulation |
US7262325B2 (en) | 2000-06-02 | 2007-08-28 | Emisphere Technologies, Inc. | Method of preparing salicylamides |
US6573237B2 (en) | 2001-03-16 | 2003-06-03 | Eli Lilly And Company | Protein formulations |
JP2005506956A (ja) | 2001-06-01 | 2005-03-10 | イーライ・リリー・アンド・カンパニー | 長時間作用性glp−1製剤 |
ES2614603T3 (es) | 2002-02-20 | 2017-06-01 | Emisphere Technologies, Inc. | Procedimiento de administración de moléculas GLP-1 |
CN1787830A (zh) * | 2003-05-14 | 2006-06-14 | 爱密斯菲尔科技公司 | 用于传送肽yy和pyy激动剂的组合物 |
CA2525168A1 (en) * | 2003-05-14 | 2004-12-02 | Emisphere Technologies, Inc. | Compositions for delivering peptide yy and pyy agonists |
EP2932981B1 (en) | 2003-09-19 | 2021-06-16 | Novo Nordisk A/S | Albumin-binding derivatives of GLP-1 |
MXPA06006745A (es) | 2003-12-18 | 2006-08-18 | Novo Nordisk As | Compuestos glp-1 novedosos. |
BRPI0417684A (pt) | 2003-12-18 | 2007-03-20 | Novo Nordisk As | composto, composição farmacêutica, e, uso de um composto |
US20060286129A1 (en) * | 2003-12-19 | 2006-12-21 | Emisphere Technologies, Inc. | Oral GLP-1 formulations |
WO2005097175A2 (en) | 2004-03-31 | 2005-10-20 | Centocor, Inc. | Human glp-1 mimetibodies, compositions, methods and uses |
CN1968919A (zh) * | 2004-04-16 | 2007-05-23 | 爱密斯菲尔科技公司 | 用于递送活性剂的8-(2-羟基苯氧基)辛基二乙醇胺和其盐 |
WO2005107773A2 (en) * | 2004-05-06 | 2005-11-17 | Emisphere Technologies, Inc. | Solid dosage form of wetted heparin |
TW200611704A (en) | 2004-07-02 | 2006-04-16 | Bristol Myers Squibb Co | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions |
WO2006005667A2 (en) | 2004-07-08 | 2006-01-19 | Novo Nordisk A/S | Polypeptide protracting tags comprising a tetrazole moiety |
NZ552558A (en) * | 2004-07-12 | 2009-11-27 | Emisphere Tech Inc | Compositions for delivering peptide YY and PYY agonists |
EP1799710A2 (en) | 2004-10-07 | 2007-06-27 | Novo Nordisk A/S | Protracted glp-1 compounds |
US8030273B2 (en) | 2004-10-07 | 2011-10-04 | Novo Nordisk A/S | Protracted exendin-4 compounds |
US20090232807A1 (en) | 2004-12-22 | 2009-09-17 | Eli Lilly And Company | Glp-1 analog fusion protein formulations |
AU2005337493A1 (en) | 2004-12-22 | 2007-04-26 | Centocor, Inc. | GLP-1 agonists, compositions, methods and uses |
ES2540929T3 (es) * | 2005-02-01 | 2015-07-14 | Emisphere Technologies, Inc. | Sistema de administración de retención gástrica y liberación controlada |
TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
JP5755398B2 (ja) | 2005-03-18 | 2015-07-29 | ノヴォ ノルディスク アー/エス | 伸長されたglp−1化合物 |
ATE509634T1 (de) | 2005-04-08 | 2011-06-15 | Amylin Pharmaceuticals Inc | Pharmazeutische formulierungen mit incretin- peptid und aprotisch-polarem lösungsmittel |
JP2009526750A (ja) | 2005-12-22 | 2009-07-23 | セントカー・インコーポレーテツド | Glp−1アゴニスト、組成物、方法および使用 |
US8927015B2 (en) | 2006-04-12 | 2015-01-06 | Emisphere Technologies, Inc. | Formulations for delivering insulin |
US8679540B2 (en) | 2006-06-09 | 2014-03-25 | Flamel Technologies | Pharmaceutical formulations for the prolonged release of active principle(s), and their applications, especially therapeutic applications |
TW200821386A (en) | 2006-07-18 | 2008-05-16 | Centocor Inc | Human GLP-1 mimetibodies, compositions, methods and uses |
WO2008019147A2 (en) | 2006-08-04 | 2008-02-14 | Amylin Pharmaceuticals, Inc. | Use of exendins, exendin agonists and glp-1 receptor agonists for altering the concentration of fibrinogen |
EP2068910A2 (en) | 2006-08-04 | 2009-06-17 | Amylin Pharmaceuticals, Inc. | Use of exendins and exendin agonists and glp-1 receptor agonists for altering lipoprotein particle size and subclass composition |
US20090318353A1 (en) | 2006-08-25 | 2009-12-24 | Novo Nordisk A/S | Acylated Exendin-4 Compounds |
BRPI0716539A2 (pt) | 2006-09-07 | 2016-11-01 | Emisphere Tech Inc | métodos para sintetização de ácido n-(8-[2-hidroxibenzoil]amino) caprílico e de sal de sódio deste |
WO2008070543A1 (en) | 2006-12-01 | 2008-06-12 | Emisphere Technologies Inc. | Improved acyclovir formulations |
TW200843794A (en) | 2006-12-21 | 2008-11-16 | Centocor Inc | Use of long-acting GLP-1 receptor agonists to improve insulin sensitivity and lipid profiles |
US20100080829A1 (en) | 2007-04-11 | 2010-04-01 | Cephalon France | Lyophilized pharmaceutical compositions and methods of making and using same |
EP1980245A1 (en) | 2007-04-11 | 2008-10-15 | Cephalon France | Bilayer lyophilized pharmaceutical compositions and methods of making and using same |
GB0707662D0 (en) * | 2007-04-20 | 2007-05-30 | Astrazeneca Ab | Chemical compounds |
EP2190873B1 (en) | 2007-09-05 | 2015-07-22 | Novo Nordisk A/S | Truncated glp-1 derivatives and their therapeutical use |
EP2679597A1 (en) | 2007-09-05 | 2014-01-01 | Novo Nordisk A/S | Glucagon-like peptide-1 derivatives and their pharmaceutical use |
EP2190460B1 (en) | 2007-09-05 | 2014-12-17 | Novo Nordisk A/S | Peptides derivatized with a-b-c-d- and their therapeutical use |
US20090186819A1 (en) | 2007-12-11 | 2009-07-23 | Marieve Carrier | Formulation of insulinotropic peptide conjugates |
JP2009274983A (ja) | 2008-05-14 | 2009-11-26 | Kowa Co | ニコチン酸アミドを含有する経口医薬組成物 |
WO2009158412A2 (en) | 2008-06-25 | 2009-12-30 | Endo Pharmaceuticals Solutions Inc. | Sustained delivery of exenatide and other polypeptides |
CN102123697B (zh) | 2008-08-18 | 2015-06-10 | 安特拉贝欧有限公司 | 用于口服给予蛋白质的方法和组合物 |
FI2341905T4 (fi) | 2008-09-04 | 2023-12-04 | Amylin Pharmaceuticals Llc | Pitkävaikutteisia formulaatioita, joissa käytetään ei-vesipitoisia kantajia |
US8425968B2 (en) | 2009-06-19 | 2013-04-23 | Pepsico., Inc. | Beverage preservative system containing pimaricin-cyclodextrin complex |
US20120065255A1 (en) | 2009-10-19 | 2012-03-15 | Nagesh Palepu | Cabazitaxel formulations and methods of preparing thereof |
PE20121362A1 (es) | 2009-11-13 | 2012-10-17 | Sanofi Aventis Deutschland | Composicion farmaceutica que comprende despro36exendina-4(1-39)-lys6-nh2, insulina gly(a21)-arg(b31)-arg(b32) y metionina |
TWI468171B (zh) | 2009-11-13 | 2015-01-11 | Sanofi Aventis Deutschland | 含glp-1激動劑及甲硫胺酸之醫藥組成物 |
CA2784757A1 (en) | 2009-12-16 | 2011-07-07 | Novo Nordisk A/S | Double-acylated glp-1 derivatives |
WO2011084618A2 (en) | 2009-12-16 | 2011-07-14 | Nod Pharmaceuticals, Inc. | Compositions and methods for oral drug delivery |
EP2538945A4 (en) | 2010-02-24 | 2013-07-24 | Emisphere Tech Inc | ORAL THERAPY WITH VITAMIN B12 |
WO2011109784A1 (en) | 2010-03-05 | 2011-09-09 | Conjuchem, Llc | Formulation of insulinotropic peptide conjugates |
WO2012062803A1 (en) | 2010-11-09 | 2012-05-18 | Novo Nordisk A/S | Double-acylated glp-1 derivatives |
BR112013014942B1 (pt) * | 2010-12-16 | 2020-01-28 | Novo Nordisk As | composições sólidas para administração, e seus usos |
CN102718858B (zh) | 2011-03-29 | 2014-07-02 | 天津药物研究院 | 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用 |
ES2612278T3 (es) | 2011-04-12 | 2017-05-16 | Novo Nordisk A/S | Derivados de GLP-1 doble-acilados |
US20140220134A1 (en) | 2011-06-24 | 2014-08-07 | Astrazeneca Pharamceuticals LP | Method for treating diabetes with extended release formulation of glp-1 receptor agonists |
EP2729481B1 (en) | 2011-07-08 | 2018-10-17 | Amylin Pharmaceuticals, LLC | Engineered polypeptides having enhanced duration of action with reduced immunogenicity |
KR102072202B1 (ko) * | 2012-03-22 | 2020-01-31 | 노보 노르디스크 에이/에스 | Glp-1 펩티드의 조성물 및 그것의 제조 |
WO2013139695A1 (en) * | 2012-03-22 | 2013-09-26 | Novo Nordisk A/S | Compositions comprising a delivery agent and preparation thereof |
ES2871328T3 (es) | 2012-06-20 | 2021-10-28 | Novo Nordisk As | Formulación de comprimido que comprende un péptido y un agente de suministro |
EP2873422A4 (en) | 2012-07-10 | 2015-12-30 | Takeda Pharmaceutical | PHARMACEUTICAL PREPARATION FOR INJECTION |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
WO2014096150A1 (en) | 2012-12-21 | 2014-06-26 | Sanofi | Dual glp1/gip or trigonal glp1/gip/glucagon agonists |
PT2991671T (pt) * | 2013-05-02 | 2018-11-05 | Novo Nordisk As | Dosagem oral de compostos de glp-1 |
CN103405753B (zh) | 2013-08-13 | 2016-05-11 | 上海仁会生物制药股份有限公司 | 稳定的促胰岛素分泌肽水针药物组合物 |
EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
WO2015086732A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues |
AR099569A1 (es) * | 2014-02-28 | 2016-08-03 | Novo Nordisk As | Derivados de insulina y los usos médicos de estos |
WO2015155151A1 (en) | 2014-04-07 | 2015-10-15 | Novo Nordisk A/S | Double-acylated glp-1 compounds |
ES2630106T3 (es) | 2014-10-07 | 2017-08-18 | Cyprumed Gmbh | Formulaciones farmacéuticas para la administración oral de fármacos peptídicos o proteicos |
CN107205949A (zh) | 2015-01-29 | 2017-09-26 | 诺和诺德股份有限公司 | 包含片芯和立即释放包衣的用于口服glp‑1给药的药物组合物 |
CA2989283A1 (en) | 2015-06-16 | 2016-12-22 | Sun Pharma Advanced Research Company Limited | Long acting liraglutide compositions |
CN108135962A (zh) | 2015-10-07 | 2018-06-08 | 塞浦路迈德有限责任公司 | 用于口服递送肽类药物的药物制剂 |
ES2835033T3 (es) | 2016-03-03 | 2021-06-21 | Novo Nordisk As | Derivados de GLP-1 y sus usos |
WO2018065634A1 (en) | 2016-10-07 | 2018-04-12 | Cyprumed Gmbh | Pharmaceutical compositions for the nasal delivery of peptide or protein drugs |
US11458201B2 (en) | 2016-10-31 | 2022-10-04 | Suda Ltd. | Mucosal active agent delivery |
AR112015A1 (es) | 2017-06-09 | 2019-09-11 | Novo Nordisk As | Composiciones sólidas para administración oral |
PL3746111T3 (pl) | 2018-02-02 | 2024-01-15 | Novo Nordisk A/S | Stałe kompozycje zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino kaprylowego i substancję poślizgową |
PL3774862T3 (pl) | 2018-04-05 | 2022-10-03 | Sun Pharmaceutical Industries Limited | Nowe analogi glp-1 |
-
2019
- 2019-05-03 TW TW108115351A patent/TWI829687B/zh active
- 2019-05-06 WO PCT/EP2019/061502 patent/WO2019215063A1/en unknown
- 2019-05-06 EP EP19720693.1A patent/EP3790575A1/en active Pending
- 2019-05-06 KR KR1020207033262A patent/KR20210008353A/ko active Search and Examination
- 2019-05-06 AU AU2019264783A patent/AU2019264783A1/en active Pending
- 2019-05-06 SG SG11202009978WA patent/SG11202009978WA/en unknown
- 2019-05-06 PE PE2020001685A patent/PE20211794A1/es unknown
- 2019-05-06 AR ARP190101193A patent/AR115283A1/es unknown
- 2019-05-06 BR BR112020021717-4A patent/BR112020021717A2/pt unknown
- 2019-05-06 MX MX2020011308A patent/MX2020011308A/es unknown
- 2019-05-06 US US17/053,511 patent/US11622996B2/en active Active
- 2019-05-06 JP JP2020562662A patent/JP7164628B2/ja active Active
- 2019-05-06 CN CN201980031030.XA patent/CN112153979A/zh active Pending
- 2019-05-06 MA MA052556A patent/MA52556A/fr unknown
- 2019-05-06 CA CA3097944A patent/CA3097944A1/en active Pending
-
2020
- 2020-10-07 IL IL277857A patent/IL277857A/en unknown
- 2020-10-13 PH PH12020551691A patent/PH12020551691A1/en unknown
- 2020-10-28 CL CL2020002797A patent/CL2020002797A1/es unknown
- 2020-11-24 CO CONC2020/0014570A patent/CO2020014570A2/es unknown
-
2022
- 2022-10-19 JP JP2022167761A patent/JP2022191439A/ja active Pending
- 2022-11-16 US US17/988,271 patent/US20230087952A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3790575A1 (en) | 2021-03-17 |
SG11202009978WA (en) | 2020-11-27 |
KR20210008353A (ko) | 2021-01-21 |
PE20211794A1 (es) | 2021-09-09 |
CL2020002797A1 (es) | 2021-02-19 |
US20210236601A1 (en) | 2021-08-05 |
IL277857A (en) | 2020-11-30 |
BR112020021717A2 (pt) | 2021-01-26 |
AR115283A1 (es) | 2020-12-16 |
CO2020014570A2 (es) | 2021-03-08 |
JP2021523149A (ja) | 2021-09-02 |
CN112153979A (zh) | 2020-12-29 |
CA3097944A1 (en) | 2019-11-14 |
JP2022191439A (ja) | 2022-12-27 |
TWI829687B (zh) | 2024-01-21 |
PH12020551691A1 (en) | 2021-07-19 |
US20230087952A1 (en) | 2023-03-23 |
JP7164628B2 (ja) | 2022-11-01 |
TW202015722A (zh) | 2020-05-01 |
US11622996B2 (en) | 2023-04-11 |
WO2019215063A1 (en) | 2019-11-14 |
WO2019215063A8 (en) | 2020-07-02 |
MA52556A (fr) | 2021-03-17 |
AU2019264783A1 (en) | 2020-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020551066A1 (en) | Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant | |
PH12020551691A1 (en) | Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid | |
MX2022000827A (es) | Composiciones solidas que comprenden un agonista del peptido similar al glucagon (glp-1), un inhibidor del transportador de sodio-glucosa 2 (sglt2) y una sal del acido n-(8-(2-hidroxibenzoil )amino)caprilico. | |
PH12020551089A1 (en) | Pyrrolopyrimidine compounds used as tlr7 agonist | |
MX2021004110A (es) | Composiciones farmaceuticas que comprenden n-(3,5- dimetoxifenil)-n'-(1-metiletil)-n-[3-(1-metil-1h- pirazol-4-il)quinoxalin-6-il]etano-1,2-diamina. | |
EA201891099A1 (ru) | 7-(тиазол-5-ил)пирролопиримида в качестве агониста рецептора tlr7 | |
MX345501B (es) | Composiciones solidas que comprenden agonista de glp-1 y sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico. | |
MX2022013612A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas. | |
MX2022004718A (es) | Omposiciones sólidas que comprenden un inhibidor de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9) y una sal de ácido n-(8-(2-hidroxibenzoil)amino)caprílico. | |
MX2022000889A (es) | Composiciones solidas que comprenden un derivado de egf(a) y una sal de acido n-(8-(2-hidroxibenzoil)amino)caprilico. | |
CY1120767T1 (el) | Συνθεσεις glp-1 πεπτιδιων και παρασκευη αυτων | |
GR1008804B (el) | Συνθεσεις για ιατρικη χρηση οι οποιες περιλαμβανουν υαλουρονικο οξυ ή αλατα αυτου, αμινοξεα, βιταμινες, ανοργανα αλατα και αλλα συστατικα |